BR112013002125A2 - derivados de c-aril glicosídeo, seus usos e seu processo de preparação, bem como composição farmacêutica - Google Patents

derivados de c-aril glicosídeo, seus usos e seu processo de preparação, bem como composição farmacêutica

Info

Publication number
BR112013002125A2
BR112013002125A2 BR112013002125A BR112013002125A BR112013002125A2 BR 112013002125 A2 BR112013002125 A2 BR 112013002125A2 BR 112013002125 A BR112013002125 A BR 112013002125A BR 112013002125 A BR112013002125 A BR 112013002125A BR 112013002125 A2 BR112013002125 A2 BR 112013002125A2
Authority
BR
Brazil
Prior art keywords
glycoside derivatives
aryl glycoside
well
pharmaceutical composition
preparation process
Prior art date
Application number
BR112013002125A
Other languages
English (en)
Inventor
Dongliang Guan
Fanglong Yang
Guangyuan Shen
Jiang Fan
Jijun Yuan
Limin Zhang
Peng Cho Tang
Qing Dong
Wangyang Tu
Yang Wang
Original Assignee
Jiangsu Hengrui Medicine Co
Shanghai Hengrui Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co, Shanghai Hengrui Pharm Co Ltd filed Critical Jiangsu Hengrui Medicine Co
Publication of BR112013002125A2 publication Critical patent/BR112013002125A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel

Abstract

derivados c-aril glicosídeo, processo e preparação e seu uso farmacêutico. são mostrados derivados c-aril glicosídeo, seus processos de preparação e usos farmacêuticos, especialmente derivados c-aril glicosídeos representados pela fórmula (i), seus sais ou estereoisômeros farmacêuticos, seus processos de preparação, composições farmacêuticas contendo os derivados e seus usos como agentes terapêuticos, especialmente como inibidores de cotransportador de glicose dependente de sódio (sglt)-1, onde cada substituinte de fórmula (i) é definido no relatório descritivo.
BR112013002125A 2010-08-10 2011-06-30 derivados de c-aril glicosídeo, seus usos e seu processo de preparação, bem como composição farmacêutica BR112013002125A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201010249618 2010-08-10
CN2010105896065A CN102372722A (zh) 2010-08-10 2010-12-06 C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用
PCT/CN2011/076680 WO2012019496A1 (zh) 2010-08-10 2011-06-30 C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
BR112013002125A2 true BR112013002125A2 (pt) 2016-05-24

Family

ID=45567352

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013002125A BR112013002125A2 (pt) 2010-08-10 2011-06-30 derivados de c-aril glicosídeo, seus usos e seu processo de preparação, bem como composição farmacêutica

Country Status (12)

Country Link
US (1) US8609622B2 (pt)
EP (1) EP2604612B1 (pt)
JP (1) JP5984808B2 (pt)
KR (1) KR101862891B1 (pt)
CN (2) CN102372722A (pt)
BR (1) BR112013002125A2 (pt)
CA (1) CA2807034C (pt)
ES (1) ES2581728T3 (pt)
HK (1) HK1167395A1 (pt)
MX (1) MX2013001098A (pt)
RU (1) RU2606501C2 (pt)
WO (1) WO2012019496A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014512399A (ja) * 2011-04-25 2014-05-22 ベイジン・プレリュード・ファーム・サイ・アンド・テック・カンパニー・リミテッド ナトリウム依存性グルコース輸送タンパク質阻害剤並びにその調製方法及び使用
WO2013038429A2 (en) 2011-09-13 2013-03-21 Panacea Biotec Ltd. Novel sglt inhibitors
CN102627535A (zh) * 2012-03-31 2012-08-08 天津药物研究院 含1,1-二苯基环丙基结构的化合物的制备方法
CN103450214B (zh) * 2012-05-29 2016-04-06 广东东阳光药业有限公司 吡喃葡萄糖基衍生物、其制备方法及其在医药上的应用
WO2014159151A1 (en) * 2013-03-14 2014-10-02 Msd International Gmbh Methods for preparing sglt2 inhibitors
CN104151306A (zh) * 2013-05-13 2014-11-19 北京新天宇科技开发有限公司 一种坎格列净的新的制备方法
WO2014187365A1 (zh) * 2013-05-24 2014-11-27 四川海思科制药有限公司 氧杂双环衍生物、制备方法及其应用
WO2014206349A1 (zh) * 2013-06-28 2014-12-31 四川海思科制药有限公司 氧杂-硫杂-双环[3.2.1]辛烷衍生物、制备方法及其用途
WO2015032272A1 (zh) * 2013-09-09 2015-03-12 江苏豪森药业股份有限公司 C-芳基葡糖苷衍生物、其制备方法及其在医药上的应用
CN104447893B (zh) * 2013-09-25 2018-01-23 广东东阳光药业有限公司 吡喃葡萄糖基衍生物及其在医药上的应用
CN104513283B (zh) * 2013-09-27 2018-01-16 广东东阳光药业有限公司 吡喃葡萄糖基衍生物及其在医药上的应用
WO2015101670A2 (en) * 2014-01-03 2015-07-09 Elexopharm Gmbh Inhibitors of 17beta-hydroxysteroid dehydrogenases type 1 and type 2
MX2016015199A (es) 2014-05-19 2017-02-28 Pfizer Compuestos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol sustituidos como agentes de direccionamiento al receptor de asialoglicoproteina (asgpr).
CN104031098A (zh) * 2014-06-21 2014-09-10 李友香 降糖药物
CN104017031A (zh) * 2014-06-21 2014-09-03 李友香 降血糖药物和组合物
CN105294785A (zh) * 2014-07-02 2016-02-03 上海阳帆医药科技有限公司 C-苯并五元杂芳环类芳基葡萄糖苷衍生物及其制备方法与用途
US20160002275A1 (en) * 2014-07-03 2016-01-07 Cadila Healthcare Limited Process for preparation and purification of canagliflozin
CN104119324B (zh) * 2014-07-23 2016-03-30 齐鲁天和惠世制药有限公司 一种卡格列净的制备方法
CN105461762B (zh) * 2014-09-27 2018-12-04 广东东阳光药业有限公司 吡喃葡萄糖基衍生物及其在医药上的应用
EP3202772B1 (en) * 2014-09-30 2020-10-28 Jiangsu Hengrui Medicine Co. Ltd. Crystal of a complex of l-proline/sodium-glucose cotransporter 2 inhibitor
EP3226874A1 (en) * 2014-12-03 2017-10-11 Sun Pharmaceutical Industries Ltd Processes for the preparation of ertugliflozin
US10294239B2 (en) 2015-05-25 2019-05-21 Sun Pharmaceutical Industries Limited Ertugliflozin co-crystals and process for their preparation
HUE051212T2 (hu) * 2016-01-04 2021-03-01 Jeil Pharmaceutical Co Ltd Kondenzált fenilgyûrût tartalmazó C-glükozid származék vagy annak gyógyászatilag elfogadható sója, eljárás annak elõállítására és azt tartalmazó gyógyászati kompozíció
CN106955273B (zh) * 2016-01-11 2020-10-20 江苏恒瑞医药股份有限公司 一种含有钠-葡萄糖协同转运蛋白2抑制剂的药物组合物
CN107686496B (zh) * 2016-08-05 2021-01-19 江苏恒瑞医药股份有限公司 一种钠-葡萄糖协同转运蛋白2抑制剂的制备方法
CN106674245B (zh) * 2017-01-10 2019-07-26 北京中海康医药科技发展有限公司 吡喃葡萄糖基衍生物的制备及医药上的应用
CN109549939A (zh) * 2017-09-26 2019-04-02 江苏恒瑞医药股份有限公司 Sglt2抑制剂和dpp-4抑制剂联合在制备治疗糖尿病的药物中的用途
CN109806397A (zh) * 2017-11-20 2019-05-28 江苏恒瑞医药股份有限公司 Sglt2抑制剂与arb联合在制备治疗高血压等疾病的药物中的用途
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
CN113330017B (zh) * 2019-12-19 2023-01-31 上海研健新药研发有限公司 一种SGLTs抑制剂的纯化方法及其应用
CN113004349A (zh) * 2019-12-19 2021-06-22 上海研健新药研发有限公司 一种SGLTs抑制剂的制备方法及其关键中间体
EP4114365A1 (en) 2020-03-05 2023-01-11 KRKA, d.d., Novo mesto Pharmaceutical composition comprising sglt2 inhibitor
WO2021245253A1 (en) 2020-06-05 2021-12-09 Krka, D.D., Novo Mesto Preparation of highly pure amorphous dapagliflozin
CN114195748B (zh) * 2020-09-17 2023-11-14 上海森辉医药有限公司 一种钠-葡萄糖协同转运蛋白2抑制剂的制备方法
CN112375087A (zh) * 2020-11-27 2021-02-19 浙江天宇药业股份有限公司 一种脯氨酸恒格列净的合成方法
CN113880701A (zh) * 2021-10-10 2022-01-04 浙江司太立制药股份有限公司 一种抗糖尿病药物中间体及其制备方法
CN116785268A (zh) * 2022-03-14 2023-09-22 江苏万邦生化医药集团有限责任公司 一种sglt-2抑制剂的药物组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
JP2004536047A (ja) * 2001-04-11 2004-12-02 ブリストル−マイヤーズ　スクイブ　カンパニー 糖尿病処置用ｃ−アリールグルコシドのアミノ酸複合体および方法
TWI254635B (en) 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
ZA200507754B (en) * 2003-03-14 2007-01-31 Astellas Pharma Inc C-glycoside derivatives and salts thereof
LT2896397T (lt) 2003-08-01 2017-11-27 Mitsubishi Tanabe Pharma Corporation Nauji junginiai, turintys inhibitorinį aktyvumą prieš nuo natrio priklausomą gliukozės transporterį
CA2664095A1 (en) * 2006-09-21 2008-03-27 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
BRPI0815708B8 (pt) 2007-08-23 2021-05-25 Theracos Sub Llc composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição
CN102149280B (zh) * 2008-07-15 2017-05-24 泰拉科斯有限公司 氘化苄基苯衍生物及其使用方法
DK2324002T3 (en) 2008-08-22 2016-12-19 Theracos Sub Llc Methods of making of sglt2 inhibitors
ATE540040T1 (de) * 2008-08-28 2012-01-15 Pfizer Dioxabicycloä3.2.1üoctan-2,3,4-triolderivate
WO2010048358A2 (en) 2008-10-22 2010-04-29 Auspex Pharmaceutical, Inc. Ethoxyphenylmethyl inhibitors of sglt2
WO2010074219A1 (ja) * 2008-12-26 2010-07-01 アステラス製薬株式会社 ベンゾチオフェン化合物
NZ599945A (en) * 2009-11-02 2014-05-30 Pfizer Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
EP2717689A4 (en) * 2011-06-13 2014-11-05 Panacea Biotec Ltd NEW SGLT HEMMER

Also Published As

Publication number Publication date
RU2606501C2 (ru) 2017-01-10
ES2581728T3 (es) 2016-09-07
KR20130095741A (ko) 2013-08-28
KR101862891B1 (ko) 2018-05-30
US20130130997A1 (en) 2013-05-23
CN102482290B (zh) 2014-01-15
US8609622B2 (en) 2013-12-17
JP2013533291A (ja) 2013-08-22
EP2604612A1 (en) 2013-06-19
CA2807034A1 (en) 2012-02-16
CN102482290A (zh) 2012-05-30
CN102372722A (zh) 2012-03-14
RU2013107748A (ru) 2014-09-20
HK1167395A1 (en) 2012-11-30
EP2604612A4 (en) 2013-07-24
JP5984808B2 (ja) 2016-09-06
EP2604612B1 (en) 2016-04-20
MX2013001098A (es) 2013-06-05
CA2807034C (en) 2019-05-07
WO2012019496A1 (zh) 2012-02-16

Similar Documents

Publication Publication Date Title
BR112013002125A2 (pt) derivados de c-aril glicosídeo, seus usos e seu processo de preparação, bem como composição farmacêutica
ECSP10010419A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos-211
CY1120690T1 (el) Κρυσταλλικη μορφη βενζυλοβενζολικου αναστολεα τουsglt2
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
BR112013032974A2 (pt) "derivados de 1,6-diazabiciclo [3,2,1]-octan-7-ona, seus usos, e composições farmacêuticas".
BR112015011158A8 (pt) triazolopirazina, seu uso e preparação farmacêutica
BR112015014438A2 (pt) composto, composição farmacêutica e uso de um composto
BR112013023876A2 (pt) derivados de pirroltriazinona como inibidores de pi3k
BR112014000938A2 (pt) quinazolinas substituídas, a preparação das mesmas e o uso das mesmas em composições farmacêuticas
BRPI0915064B8 (pt) derivados de quinoxalinadiona, seus usos, e medicamentos
BR112015007231A2 (pt) derivados de pirroltriazinona como inibidores de pi3k
BRPI0815547B8 (pt) composição farmacêutica compreendendo depsipeptídeos cíclicos, e seus usos
BRPI0821004A8 (pt) Composto derivado de aminopirazol, composição farmacêutica que o contem e uso deste
BR112012032234A2 (pt) "derivados de heteroaril imidazolona como inibidores de jak".
BRPI0907789A2 (pt) derivaldos 16-alfa e 17-alfa de glicocorticosteroides e seus usos
BRPI0920053B8 (pt) composto pirazolilaminopiridina, composição contendo o dito composto e uso do mesmo para tratar câncer
UY31865A (es) Derivados de urea heterocíclicos y métodos para la utilización de los mismos
BR112014002245A2 (pt) derivados de piridin-2(1h)-ona como inibidores de jak
UY31864A (es) Derivados de urea hetericíclica y métodos de uso de los mismos-332
BR112015029348A8 (pt) inibidores da bace, seus usos, e composição farmacêutica
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
CL2013002027A1 (es) Formas cristalinas i y ii de (r)-1-etil-3-[6-fluoro-5-[2-(1-hidroxi-1-metil-etil)pirimidin-5-il]-7(tetrahidrofuran-2-il)-1h-benzimidazol-2-il]urea, inhibidor de girasa; composicion farmeceutica; y uso poara tratar o reducir una infeccion bacteriana.
UY32694A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
BRPI0720742B8 (pt) derivados de heteroaril pirrolidinil e piperidinil cetona, seus usos e composição farmacêutica compreendo os mesmos
BR112014012983A2 (pt) derivados de pirrol

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]